TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma

Elefanti,Lisa; Sacco,Giorgia; Stagni,Camilla; Rastrelli,Marco; Menin,Chiara; Russo,Irene; Alaibac,Mauro

doi:10.3892/ol.2016.4584

TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma

Authors:
- Lisa Elefanti
- Giorgia Sacco
- Camilla Stagni
- Marco Rastrelli
- Chiara Menin
- Irene Russo
- Mauro Alaibac
View Affiliations

Affiliations: Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, Scientific Institute for Hospitalization, Treatment and Research, Padua I‑35128, Italy, Department of Medicine, Dermatology Unit, University of Padua, Padua I‑35121, Italy, Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Unit, University of Padua, Padua I‑35100, Italy, Melanoma and Soft Tissue Sarcoma Unit, Veneto Institute of Oncology, Scientific Institute for Hospitalization, Treatment and Research, Padua I‑35128, Italy
Published online on: May 16, 2016 https://doi.org/10.3892/ol.2016.4584
Pages: 275-280

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cutaneous melanoma is a life-threatening skin cancer. Its incidence is rapidly increasing, and early diagnosis is the main factor able to improve its poor prognosis. Toll‑like receptors (TLRs) are transmembrane glycoproteins that recognize pathogen‑ and damage‑associated molecular patterns, against which TLRs activate the innate immune response and initiate the adaptive immune response. Genetic variations of these receptors may alter the immune system, and are involved in evolution and susceptibility to various diseases, including cancer. The aim of the present study was to evaluate whether the presence of TLR7 glutamine (Gln) 11 leucine (Leu) polymorphism confers an increased susceptibility to cutaneous melanoma. For that purpose, a case‑control study was performed with 182 melanoma cases and 89 controls. To highlight the possible association between the aforementioned polymorphism and the susceptibility to melanoma, 93 cases of single melanoma and 89 cases of multiple primary melanoma (MPM) were compared in the present study. Since the TLR7 gene is localized on the chromosome X, the allelic frequency of the Gln11Leu polymorphism was analyzed separately in males and females. The distribution of allele frequencies between melanoma cases and controls (P=0.245) and between single melanoma and MPM cases (P=0.482) was not significant. Therefore, the present results do not suggest an association between TLR7 Gln11Leu polymorphism and susceptibility to cutaneous melanoma. Further studies are required to analyze the influence of other TLR polymorphisms on the susceptibility to malignant melanoma and the involvement of innate immunity in this malignancy.

View Figures

View References

1	Eggermont AM, Spatz A and Robert C: Cutaneous melanoma. Lancet. 383:816–827. 2014. View Article : Google Scholar : PubMed/NCBI
2	Rastrelli M, Alaibac M, Stramare R, Chiarion Sileni V, Montesco MC, Vecchiato A, Campana LG and Rossi CR: Melanoma m (zero): Diagnosis and therapy. ISRN Dermatol. 2013:6161702013.PubMed/NCBI
3	Gandini S, Autier P and Boniol M: Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol. 107:362–366. 2011. View Article : Google Scholar : PubMed/NCBI
4	Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL and Roenigk RK: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 294:681–690. 2005. View Article : Google Scholar : PubMed/NCBI
5	Birch-Johansen F, Jensen A, Mortensen L, Olesen AB and Kjær SK: Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: Rapid incidence increase among young Danish women. Int J Cancer. 127:2190–2198. 2010. View Article : Google Scholar : PubMed/NCBI
6	Rastrelli M, Tropea S, Pigozzo J, Bezzon E, Campana LG, Stramare R, Alaibac M and Rossi CR: Melanoma m1: Diagnosis and therapy. In Vivo. 28:273–285. 2014.PubMed/NCBI
7	Panasiti V, Curzio M, Roberti V, Lieto P, Devirgiliis V, Gobbi S, Naspi A, Coppola R, Lopez T, di Meo N, et al: Metastatic volume: An old oncologic concept and a new prognostic factor for stage IV melanoma patients. Dermatology. 227:55–61. 2013. View Article : Google Scholar : PubMed/NCBI
8	Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60. 2005. View Article : Google Scholar : PubMed/NCBI
9	Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 41:28–44. 2005. View Article : Google Scholar : PubMed/NCBI
10	Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 41:2040–2059. 2005. View Article : Google Scholar : PubMed/NCBI
11	Tsao H, Chin L, Garraway LA and Fisher DE: Melanoma: From mutations to medicine. Genes Dev. 26:1131–1155. 2012. View Article : Google Scholar : PubMed/NCBI
12	Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, et al: BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 30:2522–2529. 2012. View Article : Google Scholar : PubMed/NCBI
13	Platz A, Egyhazi S, Ringborg U and Hansson J: Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 1:395–405. 2008. View Article : Google Scholar : PubMed/NCBI
14	Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS and Bastian BC: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 457:599–602. 2009. View Article : Google Scholar : PubMed/NCBI
15	Navarini-Meury AA and Conrad C: Melanoma and innate immunity - Active inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines. Semin Cancer Biol. 19:84–91. 2009. View Article : Google Scholar : PubMed/NCBI
16	Iwasaki A and Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol. 5:987–995. 2004. View Article : Google Scholar : PubMed/NCBI
17	Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol. 1:135–145. 2001. View Article : Google Scholar : PubMed/NCBI
18	Burns EM and Yusuf N: Toll-like receptors and skin cancer. Front Immunol. 5:1352014. View Article : Google Scholar : PubMed/NCBI
19	Akira S and Hemmi H: Recognition of pathogen associated molecular patterns by TLR family. Immunol Lett. 85:85–95. 2003. View Article : Google Scholar : PubMed/NCBI
20	Akira S and Takeda K: Toll-like receptor signaling. Nat Rev Immunol. 4:499–511. 2004. View Article : Google Scholar : PubMed/NCBI
21	Eiró N, Ovies C, Fernandez-Garcia B, Álvarez-Cuesta CC, González L, González LO and Vizoso FJ: Expression of TLR 3, 4, 7 and 9 in cutaneous malignant melanoma: Relationship with clinicopathological characteristics and prognosis. Arch Dermatol Res. 305:59–67. 2013. View Article : Google Scholar : PubMed/NCBI
22	Miyake K: Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol. 19:3–10. 2007. View Article : Google Scholar : PubMed/NCBI
23	Häcker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB and Wagner H: CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17:6230–6240. 1998. View Article : Google Scholar : PubMed/NCBI
24	Seki E and Brenner DA: Toll-like receptors and adaptor molecules in liver disease: Update. Hepatology. 48:322–335. 2008. View Article : Google Scholar : PubMed/NCBI
25	Moynagh PN: TLR signaling and activation of IRFs: Revisiting old friends from the NF-kappaB pathway. Trends Immunol. 26:469–476. 2005. View Article : Google Scholar : PubMed/NCBI
26	Ermertcan AT, Öztürk F and Gündüz K: Toll-like receptors and skin. J Eur Acad Dermatol Venereol. 25:997–1006. 2011. View Article : Google Scholar : PubMed/NCBI
27	Saint-Jean M, Knol AC, Nguyen JM, Khammari A and Dréno B: TLR expression in human melanoma cells. Eur J Dermatol. 21:899–905. 2011.PubMed/NCBI
28	Sato Y, Goto Y, Narita N and Hoon DS: Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2(Suppl 1): 205–214. 2009. View Article : Google Scholar : PubMed/NCBI
29	Huang B, Zhao J, Unkeless JC, Feng ZH and Xiong H: TLR signaling by tumor and immune cells: A double-edged sword. Oncogene. 27:218–224. 2008. View Article : Google Scholar : PubMed/NCBI
30	Valins W, Amini S and Berman B: The expression of Toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll-like receptor modulators. J Clin Aesthet Dermatol. 3:20–29. 2010.
31	El-Omar EM, Ng MT and Hold GL: Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene. 27:244–252. 2008. View Article : Google Scholar : PubMed/NCBI
32	Maire C, Vercambre-Darras S and Desmedt E: Diagnosis of melanoma. Rev Prat. 64:61–68. 2014.(In French). PubMed/NCBI
33	Bordignon M, Bargagli E, Agostini C, Cinetto F, Baldo V, Alaibac M and Rottoli P: TLR7 Gln11Leu single nucleotide polymorphism in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 30:157–161. 2013.PubMed/NCBI
34	Wong JG, Toole JW, Demers AA, Musto G and Wiseman MC: Topical 5% imiquimod in the treatment of lentigo maligna. J Cutan Med Surg. 16:245–249. 2012.PubMed/NCBI
35	Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
36	Kutikhin AG: Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol. 72:1095–1116. 2011. View Article : Google Scholar : PubMed/NCBI
37	Tengroth L, Millrud CR, Kvarnhammar AM, Kumlien Georén S, Latif L and Cardell LO: Functional effects of Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells. PLoS One. 9:e982392014. View Article : Google Scholar : PubMed/NCBI
38	Zhang Y, Yang H, Barnie PA, Yang P, Su Z, Chen J, Jiao Z, Lu L, Wang S and Xu H: The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer. Int J Med Sci. 11:608–613. 2014. View Article : Google Scholar : PubMed/NCBI
39	Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, Young HA, Trinchieri G and Wink DA: Molecular pathways: Toll-like receptors in the tumor microenvironment - poor prognosis or new therapeutic opportunity. Clin Cancer Res. 19:1340–1346. 2013. View Article : Google Scholar : PubMed/NCBI
40	Krieg AM: Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep. 6:88–95. 2004. View Article : Google Scholar : PubMed/NCBI
41	Aspord C, Tramcourt L, Leloup C, et al: Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization. J Invest Dermatol. 134:2551–2561. 2014. View Article : Google Scholar : PubMed/NCBI
42	Wang D, Precopio M, Lan T, Yu D, Tang JX, Kandimalla ER and Agrawal S: Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol Cancer Ther. 9:1788–1797. 2010. View Article : Google Scholar : PubMed/NCBI
43	Wang J, Kobayashi M, Han M, Choi S, Takano M, Hashino S, Tanaka J, Kondoh T, Kawamura K and Hosokawa M: MyD88 is involved in the signaling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells. Br J Haematol. 118:638–645. 2002. View Article : Google Scholar : PubMed/NCBI
44	Tyring S, Conant M, Marini M, Van Der Meijden W and Washenik K: Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol. 41:810–816. 2002. View Article : Google Scholar : PubMed/NCBI
45	Gupta AK, Cherman AM and Tyring SK: Viral and nonviral uses of imiquimod: A review. J Cutan Med Surg. 8:338–352. 2004. View Article : Google Scholar : PubMed/NCBI
46	Yates CM and Sternberg MJ: The effects of non-synonymous single nucleotide polymorphisms (nsSNPs) on protein-protein interactions. J Mol Biol. 425:3949–3963. 2013. View Article : Google Scholar : PubMed/NCBI
47	Gast A, Bermejo JL, Claus R, Brandt A, Weires M, Weber A, Plass C, Sucker A, Hemminki K, Schadendorf D and Kumar R: Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS One. 6:e243702011. View Article : Google Scholar : PubMed/NCBI
48	Askar E, Ramadori G and Mihm S: Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection. J Med Virol. 82:1859–1868. 2010. View Article : Google Scholar : PubMed/NCBI